The primary objective of this study is to evaluate the tolerability and safety of MWAV201 in patients with Wilson disease.
Male or female aged 18 and 65 years inclusive;
Confirmed diagnosis of Wilson disease;
Low copper diet and standardized medication for ≥ 1 year;
Stable Wilson disease for ≥ 1 year;
Significant hepatic inflammation as evidenced by liver function test.
Liver biopsy or liver stiffness measurement show progressive liver fibrosis.
Laboratory tests or clinical symptoms indicate decreased liver reserve function.
Other chronic liver disease (such as hepatitis B).
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Collaborator